FDA approves serial liquid biopsy testing - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

  • By

  • Kathryn Wighton

  • September 8, 2026

  • 2 min

Share

Original Source(s)

FDA approves serial liquid biopsy testing

  • by Kathryn Wighton

  • September 8, 2026

Related Content

Commentary: Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins

Case Report: Possible spatially-distinct de novo invasive cervical carcinoma in the setting of isolated persistent HPV16 after ALA-PDT-mediated histological clearance of CIN3

Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges